


Oligonucleotide-based medicines (OBMs) have the potential to interrupt and reverse a huge range of genetic diseases, but there are too many possible OBMs to conduct safety and toxicity screening using old-fashioned trial-and-error approaches. Creyon takes a combined in vivo, in vitro, and in silico approach to solving that problem. The company knows how its library of survey compounds affects mammalian organs and whether they’re effective in patient cells; using this information, it has trained machine-learning algorithms to predict whether novel OBMs will have toxic or immune-stimulating effects.
News & Insights
In The Media
With a new CEO, oligonucleotide biotech Creyon forges Eli Lilly partnership
Baby's inspiring battle against an ultra-rare disease
Creyon Bio Secures $40M in Seed and Series A Financing
Creyon Bio is Creating Precision Medicines for Diseases Common and Rare
Explore Companies

Grove Biopharma
Putting protein-like drugs inside cells to fight cancer and neurodegeneration

Syntax Bio
Programming stem cells to differentiate into desired cell types, faster

Fable Therapeutics
Using state-of-the-art machine learning models to create custom-build protein drugs

Nilo Therapeutics
Mapping the brain-body axis to achieve proper immune balance